Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Copernicus to Receive Increased Support from Cystic Fibrosis Foundation Therapeutics to Further Development of its Non-Viral Gene Therapy for Cystic F

Abstract:
Copernicus Therapeutics, Inc., announced today it will receive up to $5.2 million from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) to support continued development of a potential gene therapy for cystic fibrosis. This continued funding is a result of satisfactory progress shown in 2006 and represents a significant increase in funding over that received in 2006.

Copernicus to Receive Increased Support from Cystic Fibrosis Foundation Therapeutics to Further Development of its Non-Viral Gene Therapy for Cystic F

Cleveland, OH | Posted on February 15th, 2007

Copernicus' unique, non-viral nanoparticle formulation is intended to deliver a normal copy of the CF gene to the affected lung cells of CF patients, and may provide a therapy that treats the root cause of CF. Copernicus' first clinical trial, supported by CFFT, demonstrated the desired safety profile and encouraging biological changes were observed.

Cystic fibrosis is the most common fatal genetic disease in the United States, affecting approximately 30,000 children and adults. It causes serious lung infections and digestive complications. About 10 million Americans are unknowing carriers of a CF gene.

"We have had a productive relationship for a number of years with CFFT and we share the common goal of providing a safe and effective therapeutic for people with CF," said Robert C. Moen, M.D., Ph.D., president and CEO of Copernicus. "Our relationship with CFFT involves not only financial support, but also support at the scientific level through a research review committee comprised of outstanding academic scientists active in the areas required for development of a successful product. We look forward to working with CFFT in meeting the critical need for an effective gene-based therapy for the lung manifestations of CF."

"We are encouraged by the promise of Copernicus' technology and the scientific rigor the firm is applying to the development process," said Robert J. Beall, Ph.D., president and CEO of the CF Foundation and CFFT. "Gene-based therapies offer hope for potentially lifesaving treatments that tackle the root cause of CF, rather than just the symptoms. We are grateful for the many people that generously support CFF and provide CFFT with critical financial resources to support this kind of research."

####

About Cystic Fibrosis Foundation, CFFT, and Copernicus
Copernicus Therapeutics, Inc., a privately held biotechnology company, is dedicated to delivering the promise of nucleic acid therapeutics. The same technology that is being tested for its ability to deliver the CF gene to the lung of CF patients can be applied to treating serious lung infections caused by influenza A, bird flu, and other respiratory viruses, as well as for treating a variety of blinding disorders. The Copernicus multi-component delivery platform can be used to develop nucleic acid therapies for numerous human diseases. Additional information about Copernicus is available at http://www.cgsys.com .

The mission of the Cystic Fibrosis Foundation is to assure the development of the means to cure and control CF, and to improve the quality of life for those with the disease. CFFT is the nonprofit drug development affiliate of the CF Foundation that operates drug discovery, development and evaluation efforts. Total support for CFFT is provided by the CF Foundation. The CF Foundation has initiated a special gifts campaign, Milestones to a Cure, with a target goal of $175 million to support programs like the one with Copernicus. For more information about CF, the CF Foundation or CFFT, call (800) FIGHT CF or visit http://www.cff.org .

For more information, please click here

Contacts:
Copernicus Therapeutics, Inc.
Robert C. Moen, M.D., Ph.D., President & CEO,
216-231-0227 x26
or
Copernicus Therapeutics, Inc.
Mark J. Cooper, M.D., Sr. V.P. of Science and
Medical Affairs, 216-231-0227 x23
or
Cystic Fibrosis Foundation
Laurie Fink, Director of Media Relations,
301-841-2602

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Human Interest/Art

Iran-Made Respiratory Nano Masks Provided to Hajj Pilgrims October 23rd, 2014

Japanese gold leaf artists worked on a nano-scale: Study demonstrates X-ray fluorescence spectroscopy is a non-destructive way to date artwork July 3rd, 2014

Harry Potter-style invisibility cloaks: A real possibility next Christmas? Forget socks and shaving foam, the big kids of tomorrow want an invisible cloak for Christmas December 19th, 2013

Chicago Awareness Organization First Not-for-Profit to Sponsor Dog Training to Detect Ovarian Cancer Odorants December 12th, 2013

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014

Crystallizing the DNA nanotechnology dream: Scientists have designed the first large DNA crystals with precisely prescribed depths and complex 3D features, which could create revolutionary nanodevices October 20th, 2014

QD Vision Wins Prestigious Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency October 16th, 2014

Beyond LEDs: Brighter, new energy-saving flat panel lights based on carbon nanotubes - Planar light source using a phosphor screen with highly crystalline single-walled carbon nanotubes (SWCNTs) as field emitters demonstrates its potential for energy-efficient lighting device October 14th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE